Catalent (CTLT) has been frequently in the news spanning over a range of topics. A significant number are linked to its
$16.5 billion acquisition by
Novo Holdings (NVO), a deal which has been frequently discussed, and received
widespread approval from Cathalent's stockholders, though it has also led to investigations by Robbins LLP as well as FTC. Regarding finance, analysis shows Cathalent potentially
undervalued by 24%, but there's been notable
insider trading and
divesting by various advisories and banks. Its
Q3 2024 results underperformed estimates, which received heavy coverage, sending stocks tumbling.
Catalent has seen unusually-high trading volumes on these developments, with some investors regrettably losing 47% over the last three years. CTLP's
expansion of its Clinical Supply Facility in Schorndorf,
Germany was widely reported. Other areas of development include
the completion of incremental term loans and
its strategic merger with Creek Parent, Inc. Lastly, activist shareholder
Elliott is pushing Cathalent to build value, and is thought to be considering various options following a deal.
Catalent CTLT News Analytics from Mon, 29 Aug 2022 07:00:00 GMT to Sat, 17 Aug 2024 18:32:22 GMT -
Rating 3
- Innovation -4
- Information 9
- Rumor -7
